A phase II study of DuP 937 (Teloxantrone) in metastatic malignant melanoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCICCTG)

Ann Oncol. 1993 Sep;4(8):695-6. doi: 10.1093/oxfordjournals.annonc.a058628.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthraquinones / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Canada
  • Humans
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Neoplasm Metastasis
  • Pyrazoles / therapeutic use*

Substances

  • Anthraquinones
  • Antineoplastic Agents
  • Pyrazoles
  • teloxantrone